Janux Therapeutics (JANX) Retained Earnings (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Retained Earnings data on file, last reported at -$375.7 million in Q1 2026.

• Retained Earnings for Q1 2026 came in at -$375.7 million, down 43.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$375.7 million (down 43.8% YoY), and the FY2025 annual result was $4.3 million, up 99.54% from the prior year.
• Retained Earnings slipped to -$375.7 million in Q1 2026 per JANX's latest filing, from $4.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $4.3 million in Q4 2025 and troughed at -$375.7 million in Q1 2026.
• A 5-year average of -$157.0 million and a median of -$157.0 million in 2023 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings tumbled 393454.17% in 2022, then jumped 101.28% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$1.5 million in 2022, then plunged by 10894.33% to -$168.8 million in 2023, then jumped by 101.28% to $2.2 million in 2024, then soared by 99.54% to $4.3 million in 2025, then tumbled by 8804.82% to -$375.7 million in 2026.
• Business Quant data shows JANX's Retained Earnings at -$375.7 million in Q1 2026, $4.3 million in Q4 2025, and -$319.4 million in Q3 2025.